BUYOUT OF SOLTA - LAW FIRM SEEKS HIGHER PRICE FOR SHAREHOLDERS
December 16, 2013
New York, New York
Tripp Levy PLLC, a leading securities and shareholder rights law firm that represents shareholders throughout the nation, announces that it is investigating the acquisition of Solta Medical, Inc. on behalf of its shareholders. Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that it has entered into a definitive agreement under which Valeant will acquire all of the outstanding common stock of Solta Medical, Inc. (SLTM) for $2.92 per share in cash.
The investigation concerns whether the board of directors of Solta breached their fiduciary duties by not engaging in a full and fair process to insure shareholders received the maximum value for their shares, while not, at the same time, seeking personal benefits for their own self-interests. Indeed, analysts have projected that the true inherent going forward value of Solta is worth at least $4 per share.
If you are a shareholder of Solta and would like additional information regarding this matter at no cost or expense, please contact us toll free at 1-877-772-3975 or email at contact @ tripplevy
Tripp Levy PLLC has extensive experience in mergers and takeovers and has assisted in the recovery of hundreds of millions of dollars for shareholders. Attorney advertising. Prior results do not indicate a similar outcome.
Tripp Levy PLLC announces that a merger agreement entered into between Solta and Valeant has been filed. The merger agreement contains a termination fee of approx. $9 million if another company wants to make a higher offer, along with other voting, matching, and non-solicitation rights. If you are a shareholder of Solta and would like a copy of the merger agreement along with an explanation as to how it may affect your rights as a shareholder, please contact us at 1-877-772-3975.